PBC

FloQast Supercharges Compliance Management Solution with New Features Supporting Diverse Compliance Frameworks

Retrieved on: 
星期四, 五月 9, 2024
Continuity, Internal, ROI, Automation, Revenue cycle management, GDPR, Variety, Risk, Comprehension, Controller, Risk management, ISO, Workflow, SOC 2, CPA, Documentation, RCM, SOC, GRC, Risk assessment, SOX, Accounting, PBC, CFOS, Audit

FloQast Compliance Management and these latest enhancements address these issues by centralizing compliance management from risk assessment and control design to execution, testing, remediation, and optimization.

Key Points: 
  • FloQast Compliance Management and these latest enhancements address these issues by centralizing compliance management from risk assessment and control design to execution, testing, remediation, and optimization.
  • FloQast’s enhancement of FloQast Compliance Management provides CFOs and Controllers with more cost-effective programs and peace of mind during audits."
  • Enhanced FloQast Compliance Management capabilities include:
    Proactive Management of the Risk Assessment Process: FloQast Compliance Management offers a solution beyond spreadsheets, safeguarding data integrity for compliance documents.
  • FloQast Compliance Management offers custom fields, enabling tailored solutions for multi-framework compliance programs, leading to faster ROI and cost savings.

Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference

Retrieved on: 
星期四, 五月 9, 2024
Bezafibrate, Gastrointestinal disease, Learning, Intercept, Abstract, Aspartic acid, Primary biliary cholangitis, Fibrosis, Intercept Pharmaceuticals, Therapy, Senior, Liver, Obeticholic acid, DDW, Hepatology, PBC, Risk, Head, Pharmaceutical industry

MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abstracts on primary biliary cholangitis (PBC) will be presented at Digestive Disease Week® (DDW) 2024.

Key Points: 
  • MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abstracts on primary biliary cholangitis (PBC) will be presented at Digestive Disease Week® (DDW) 2024.
  • “These data, along with new analyses from our landmark Phase 3 POISE trial, showcase our continued commitment to helping improve the lives of people living with PBC.
  • A full list of sessions at DDW 2024 is available at www.ddw.org .
  • Attendees of DDW can visit Intercept at booths #3741 and #3828 throughout the meeting.

Ironwood Pharmaceuticals Reports First Quarter 2024 Results

Retrieved on: 
星期四, 五月 9, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, PS, Phase, Capsule, The Lancet, Gastrointestinal disease, Safety, AbbVie, Food, Interstitial cystitis, SBS, Depreciation, Interest, Trial of the century, Endometriosis, Research, Hepatology, IQVIA, Disease, Autoimmune disease, Patient, Liver, Acquisition, Short bowel syndrome, Constipation, DDW, STARS, Primary biliary cholangitis, Bank statement, Adjustment, Standard of care, Clinical trial, PBC, GAAP, Food and Drug Administration, Income tax, Ageing, Pharmaceutical industry

LINZESS commercial margin, excluding the gross-to-net change in estimate, was 71% in the first quarter of 2024, compared to 73% in the first quarter of 2023.

Key Points: 
  • LINZESS commercial margin, excluding the gross-to-net change in estimate, was 71% in the first quarter of 2024, compared to 73% in the first quarter of 2023.
  • Total revenue in the first quarter of 2024 was $74.9 million, compared to $104.1 million in the first quarter of 2023.
  • Operating expenses in the first quarter of 2024 were $63.9 million, compared to $44.0 million in the first quarter of 2023.
  • Ironwood generated $45.0 million in cash from operations in the first quarter of 2024, compared to $80.2 million in cash from operations in the first quarter of 2023.

Zevia Announces First Quarter 2024 Results

Retrieved on: 
星期三, 五月 8, 2024
Retail, Supermarket, Food, Beverage, DSD, Pacific Northwest, Investment, Acceleration, Marketing, Webcast, IPO, SKU, Loss, PBC, Drink, GAAP, Growth

Zevia PBC (“Zevia” or the “Company”) (NYSE: ZVIA), the company bringing naturally delicious, zero sugar, clean-label beverages across usage occasions today reported results for the first quarter ended March 31, 2024.

Key Points: 
  • Zevia PBC (“Zevia” or the “Company”) (NYSE: ZVIA), the company bringing naturally delicious, zero sugar, clean-label beverages across usage occasions today reported results for the first quarter ended March 31, 2024.
  • Equity-based compensation, a non-cash expense, was $1.5 million in the first quarter of 2024, compared to $2.4 million in the first quarter of 2023.
  • Net loss for the first quarter of 2024 was $7.2 million, compared to net loss of $2.9 million in the first quarter of 2023.
  • Adjusted EBITDA loss was $5.5 million in the first quarter of 2024, compared to an Adjusted EBITDA loss of $0.5 million in the first quarter of 2023.

Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results

Retrieved on: 
星期三, 五月 8, 2024
Table, Acceleration, International, Research, Security (finance), Bank statement, Clinical trial, PBC, Telephone, GAAP

TUCSON, Ariz., May 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial preliminary results for the first quarter ended March 31, 2024.

Key Points: 
  • TUCSON, Ariz., May 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial preliminary results for the first quarter ended March 31, 2024.
  • Notable Wave program achievements during the quarter included:
    Pre-clinical trial site installation of the Accelerate Wave system for Gram-Negative Positive Blood Culture (PBC) samples.
  • Full financial results for the quarter ended March 31, 2024 will be filed on Form 10-Q through the Securities and Exchange Commission's (SEC) website at http://www.sec.gov .
  • Management will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to review first quarter 2024 results.

Mark Cuban Cost Plus Drug Company Teams Up with RxLink to Bring Pharmacy Cost Transparency to Patients of Leading Health Systems

Retrieved on: 
星期二, 五月 7, 2024
Prescription, SMS, Organization, Patient, Cost Plus Drugs, Pharmacy, PBC, Partnership, Pharmaceutical industry

DOVER, Del., May 7, 2024 /PRNewswire/ -- Today, RxLink, a firm founded with the same commitment to price transparency in prescription medicine as Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) announced a new collaboration to connect patients of leading health systems with Cost Plus Drugs' offering of safe medicines at the lowest possible price.

Key Points: 
  • Patients Automatically Receive Information on Pricing of Prescribed Medications, Including Cost Plus Drugs' Transparent Pricing
    DOVER, Del., May 7, 2024 /PRNewswire/ -- Today, RxLink, a firm founded with the same commitment to price transparency in prescription medicine as Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) announced a new collaboration to connect patients of leading health systems with Cost Plus Drugs' offering of safe medicines at the lowest possible price.
  • The MedMap™ now includes Cost Plus Drugs and has already identified and surfaced over $162,000 in patient savings after only 3 months of including Cost Plus Drugs pricing.
  • "We are excited to work with RxLink to bring lower prescription drug prices to consumers," said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company.
  • "Cost Plus Drugs and RxLink share a common goal of providing consumers the lowest possible price for their prescription medication.

Lykos Therapeutics Announces FDA Advisory Committee Meeting to Review Investigational MDMA-Assisted Therapy for PTSD

Retrieved on: 
星期一, 五月 6, 2024
Federal Register, FDA, Capsule, Person, Priority review, NDA, Post-traumatic stress disorder, Food, Safety, PTSD, MAPS, Psychotherapy, PDAC, MDMA, PDUFA, Volume, OPH, Diagnosis, PBC, Therapy, SAN, Pharmaceutical industry

This will be the first FDA advisory committee meeting to review a potential new PTSD treatment in 25 years.1 As with all advisory committee meetings, there will be an open public hearing (OPH) session, during which interested persons may present relevant information or views orally or in writing.

Key Points: 
  • This will be the first FDA advisory committee meeting to review a potential new PTSD treatment in 25 years.1 As with all advisory committee meetings, there will be an open public hearing (OPH) session, during which interested persons may present relevant information or views orally or in writing.
  • "This will be the first MDMA-assisted therapy and psychedelic-assisted therapy to be reviewed by the Psychopharmacologic Drugs Advisory Committee, a significant milestone in the field of psychedelic medicine, resulting from decades of clinical research and advocacy," said Amy Emerson, Chief Executive Officer of Lykos Therapeutics.
  • The FDA granted the application Priority Review and has assigned a Prescription Drug User Fee Act ("PDUFA") target action date of August 11, 2024.
  • At Lykos Therapeutics, a public benefit corporation (PBC) founded by MAPS, our mission is to transform mental healthcare.

Palm Beach Capital Exceeds $350 Million For Its Sixth Fund

Retrieved on: 
星期五, 五月 3, 2024
Asset Management, Professional Services, Finance, LLP, Business development, Insurance, Consultant, Partner (business rank), PBC

Palm Beach Capital (“PBC”), a middle market private equity firm, announced today that it has closed Palm Beach Capital Fund VI, L.P. (“Fund VI”), its sixth private equity fund dedicated to partnering with founders, business owners, and management teams in key sector focus areas.

Key Points: 
  • Palm Beach Capital (“PBC”), a middle market private equity firm, announced today that it has closed Palm Beach Capital Fund VI, L.P. (“Fund VI”), its sixth private equity fund dedicated to partnering with founders, business owners, and management teams in key sector focus areas.
  • Fund VI exceeded $350 million, significantly surpassing its target of $275 million.
  • Fund VI’s broad and global investor base includes diversified financial institutions, insurance companies, pension funds, foundations, endowments, consultants, funds of funds, and institutional family offices.
  • PBC’s general partners and professionals are significant personal investors in Fund VI and remain, collectively, one of the largest investors across all active PBC funds.

Lykos Therapeutics Strengthens Commercial Organization with Key Hires as it Prepares for Potential Commercial Launch

Retrieved on: 
星期五, 五月 3, 2024
Social stigma, FDA, University, Capsule, Social work, CCO, Simmons University, Safety, Food, Marketing, Coy, PTSD, MAPS, Market access, Policy, MDMA, Senior, Psychology, Bristol Myers Squibb, Cell biology, Patient advocacy, Multimedia, PBC, Therapy, SAN, McGill University, Pharmaceutical industry

Coy Stout has also joined Lykos as Vice President (VP) of Market Access,  a critical function in the growing commercial organization.

Key Points: 
  • Coy Stout has also joined Lykos as Vice President (VP) of Market Access,  a critical function in the growing commercial organization.
  • "The appointment of Allison, our first chief commercial officer, marks a critical milestone as we build out our commercial organization and prepare for a potential product launch of MDMA-assisted therapy if approved by the FDA," said Amy Emerson, Chief Executive Officer of Lykos Therapeutics.
  • Ms. Rosenthal brings to Lykos more than 25 years of pharmaceutical experience introducing innovative therapies.
  • At Lykos Therapeutics, a public benefit corporation (PBC) founded by MAPS, our mission is to transform mental healthcare.

PBC publishes 3rd annual Cannabis Banking Directory

Retrieved on: 
星期三, 五月 1, 2024
Sale, Congress, HR, Credit union, Insurance, Conference, Directory, Legislation, Member, Government, PBC, Knowledge, Drug

The PBC Cannabis Banking Directory is one of several free Industry Resources offered by PBC and complements the recent launch of the PBC Certification Program , which establishes a standardized baseline of knowledge for cannabis bankers and compliance professionals, to meet the industry's demand for qualified talent.

Key Points: 
  • The PBC Cannabis Banking Directory is one of several free Industry Resources offered by PBC and complements the recent launch of the PBC Certification Program , which establishes a standardized baseline of knowledge for cannabis bankers and compliance professionals, to meet the industry's demand for qualified talent.
  • The PBC Level I Certificate course is live and is designed for learners keen on grasping the foundational concepts of cannabis banking and compliance.
  • PBC's premier offering is a two-day conference held in Washington, D.C. that convenes top executives in the cannabis banking industry, as well as those working across cannabis compliance, legislation, regulation, and ancillary businesses that address seed-to-sale tracking, cannabis data, 280E taxes, HR & Payroll, insurance and more.
  • Past participants have included State Cannabis Regulators, Banking Regulators, IRS Commissioners, Senators, Members of Congress, and other federal and state regulators and legislators.